NL-OMON35117
Completed
Not Applicable
Obesity treatment and changes in glucose tolerance: the role of physical activity and sleep - Obesity treatment and glucose tolerance
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- obesitas
- Sponsor
- niversiteit Maastricht
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subject must be enrolled or in the intake procedure of the CO\-EUR treatment programme
- •minimum 18 years of age
- •BMI \> 30 kg/m2
- •The inclusioncriteria of the CO\-EUR treatment center are also minimum 18 years of age and a BMI \> 30kg/m2
Exclusion Criteria
- •insulin dependent diabetics are excluded
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Study on glycemic control, weight, body fat and insulin resistance in SGLT2 inhibitor-treated Japanese patientsType 2 diabetesJPRN-UMIN000016635Medical Corporation H.E.C Science Clinic30
Completed
Not Applicable
A study in subjects with impaired glucose tolerance (IGT) to evaluate effects of AO-128 on prevention of type 2 diabetes mellitus (Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison)Impaired glucose tolerance (IGT)JPRN-UMIN000001109Takeda Pharmaceutical Company Limited1,782
Completed
Not Applicable
Effects for glucose metabolism, body composition, and circulatory dynamics of SGLT2 inhibitorType 2 diabetes mellitusJPRN-UMIN000017195Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki30
Completed
Phase 2
Study of the glucose metabolism-improving effect of the 12-week intake of beverages containing lactic acid bacteriaHyperglycemiaJPRN-UMIN000023466HUMA R&D CORP130
Completed
Phase 2
Study of the glucose metabolism-improving effect of the 12-week intake of food containing lactic acid bacteria: A randomized, double-blind, placebo-controlled, parallel-group studyHyperglycemiaJPRN-UMIN000032837KSO Corporation130